What side effects are associated with this type of intervention?

Common treatments for brain metastases, including HER3-directed antibody-drug conjugates like Patritumab Deruxtecan, often have side effects such as neutropenia, anemia, thrombocytopenia, and interstitial lung disease or pneumonitis. Other systemic therapies for brain metastases, such as tyrosine kinase inhibitors and immune checkpoint inhibitors, can cause fatigue, diarrhea, rash, and liver enzyme abnormalities. Additionally, treatments targeting the VEGF pathway may lead to neurovascular events like ischemic or hemorrhagic strokes, transient ischemic attacks, and posterior reversible encephalopathy syndrome.

What prior FDA approvals exist?

FDA approvals for the treatment of brain metastases have included several next-generation tyrosine kinase inhibitors and immune checkpoint inhibitors, particularly for tumors like NSCLC, melanoma, and breast cancer. While specific approvals for HER3-directed antibody-drug conjugates like Patritumab Deruxtecan are not detailed, similar drugs such as fam-trastuzumab deruxtecan (a HER2-directed antibody-drug conjugate) have shown efficacy in metastatic settings, including brain metastases. These treatments aim to prolong survival and improve quality of life by targeting specific molecular pathways involved in cancer progression.

What other types of research exist?

Promising alternatives to Patritumab Deruxtecan for brain metastases patients include entrectinib and repotrectinib. Entrectinib has shown efficacy in NTRK fusion-positive cancers with CNS penetration, while repotrectinib has demonstrated potent antitumor activity and efficient CNS penetration in ROS1-rearranged non-small cell lung cancer.

← Back to Search

Monoclonal Antibodies

Patritumab Deruxtecan for Brain Tumor (PARAMETer Trial)

Q: What is the mechanism of action of this treatment?

Common treatments for brain metastases, such as antibody-drug conjugates (ADCs) like Patritumab Deruxtecan, work by combining a monoclonal antibody targeting a specific tumor antigen (e.g., HER3) with a cytotoxic drug. This targeted approach allows for the direct delivery of chemotherapy to cancer cells, reducing harm to healthy cells. Other treatments include tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors, which target specific pathways involved in tumor growth and immune evasion. These targeted therapies are particularly important for brain metastases patients as they offer the potential for more effective and less toxic treatments, addressing the challenges of drug delivery to the brain.

Phase < 1

Waitlist Available

Research Sponsored by Mustafa Khasraw, MBChB, MD, FRCP, FRACP

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 40 days

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing if a targeted cancer drug called patritumab deruxtecan can reach brain tumors in patients whose cancer has spread to the brain. The drug works by using an antibody to deliver chemotherapy directly to the cancer cells. Patients will receive the drug before surgery to see how well it works and if it is safe.

Who is the study for?

This trial is for adults with new or returning brain tumors that can be removed by surgery. They should have minimal symptoms, agree to a craniotomy, and use birth control if needed. Eligible cancers include melanoma, stomach, breast, colorectal, bladder, ovarian cancer etc., with good performance status and organ function.

What is being tested?

The study tests patritumab deruxtecan (HER3-DXd) in patients before they undergo brain tumor removal surgery. It aims to see if the drug reaches the brain tissue after one dose.

What are the potential side effects?

Potential side effects of patritumab deruxtecan may include reactions related to drug infusion, issues affecting organs like lungs or liver due to pre-existing conditions or allergies specific to this medication.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 40 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~40 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 40 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Brain

Secondary study objectives

Assess the evidence of tumor cell death via histopathological examination and measurement of γH2AX levels in tumor tissue.

Brain

Craniotomy

Side effects data

From 2023 Phase 1 & 2 trial • 182 Patients • NCT02980341

73%

Nausea

67%

Aspartate aminotransferase increased

67%

Platelet count decreased

67%

Neutrophil count decreased

60%

Decreased appetite

60%

White blood cell count decreased

60%

Alanine aminotransferase increased

53%

Vomiting

53%

Anaemia

40%

Stomatitis

40%

Nasopharyngitis

33%

Diarrhoea

33%

Fatigue

27%

Hypoalbuminaemia

20%

Dyspnoea

20%

Alopecia

20%

Hypokalaemia

20%

Blood alkaline phosphatase increased

20%

Headache

20%

Pain

20%

Constipation

13%

Epistaxis

13%

Malaise

13%

Pyrexia

13%

Dysgeusia

13%

Urticaria

13%

Dry skin

13%

Rash maculo-papular

13%

Electrocardiogram QT prolonged

13%

Peripheral sensory neuropathy

13%

Cough

Iodine allergy

Strabismus

Eczema

Somnolence

Pubic pain

Thrombocytopenia

Hypomagnesaemia

Hypoglycaemia

Parkinsonism

Conjunctival deposit

Seborrhoeic dermatitis

Arthralgia

Weight decreased

Gamma-glutamyltransferase increased

Leukopenia

Acne

Pneumonia

Hand-foot-and-mouth disease

Embolism

Skin sensitisation

Paronychia

Dyspepsia

Purpura

Hyponatraemia

Herpes zoster

Neuropathy peripheral

Pneumonitis

Urinary tract infection

Neutropenia

Agitation

Myalgia

Menstruation irregular

Performance status decreased

Lymphocyte count decreased

Haemorrhoids

Infusion related reaction

Intraocular pressure increased

Vertigo

Upper-airway cough syndrome

Rash

Oedema peripheral

Mucosal inflammation

100%

80%

60%

40%

20%

Study treatment Arm

Dose Escalation/Dose Finding: Cohort 4.8 mg/kg

Dose Finding: 3.2/4.8/6.4 mg/kg

Dose Escalation/Dose Finding: Cohort 6.4 mg/kg

Dose Expansion: HER3-High 6.4 mg/kg

Dose Expansion: HER3 High 4.8 mg/kg

Dose Escalation: Cohort 1.6 mg/kg

Dose Expansion: TNBC 6.4 mg/kg

Dose Expansion: HER3-Low 6.4 mg/kg

Dose Finding: 4.2/6.4 mg/kg

Dose Escalation: Cohort 8.0 mg/kg

Dose Escalation: Cohort 3.2 mg/kg

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Patritumab deruxtecanExperimental Treatment1 Intervention

15 participants with surgically-resectable brain metastases from multiple solid tumor primary histologies known to express HER3 will be treated. Patritumab deruxtecan (HER3-DXd) will be administered IV 5.6 mg/kg as a single dose 1-3 days prior to planned craniotomy and resection of BrM. Participants will undergo specimen collection prior to and during the planned craniotomy, including tumor, blood, and cerebrospinal fluid (CSF).

Do I qualify?Apply below to find out

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.

Mechanism Of Action

Side Effect Profile

Prior Approvals

Other Research

Common treatments for brain metastases, such as antibody-drug conjugates (ADCs) like Patritumab Deruxtecan, work by combining a monoclonal antibody targeting a specific tumor antigen (e.g., HER3) with a cytotoxic drug. This targeted approach allows for the direct delivery of chemotherapy to cancer cells, reducing harm to healthy cells. Other treatments include tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors, which target specific pathways involved in tumor growth and immune evasion. These targeted therapies are particularly important for brain metastases patients as they offer the potential for more effective and less toxic treatments, addressing the challenges of drug delivery to the brain.

Anti-EGFR VHH-armed death receptor ligand-engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers.Brain metastases in metastatic cancer: a review of recent advances in systemic therapies.